title: MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
abstract: The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding and virion entry to cells, is immunodominant and induces neutralizing antibodies in vivo, all of which, make the S protein an ideal target for anti-MERS-CoV vaccines. In this study, we demonstrate protection induced by vaccination with a recombinant MERS-CoV S nanoparticle vaccine and Matrix-M1 adjuvant combination in mice. The MERS-CoV S nanoparticle vaccine produced high titer anti-S neutralizing antibody and protected mice from MERS-CoV infection in vivo.
authors.affiliation: University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Coleman
authors.affiliation: University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States.
authors.forename: Thiagarajan
authors.initials: T
authors.lastname: Venkataraman
authors.affiliation: Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.
authors.forename: Ye V
authors.initials: YV
authors.lastname: Liu
authors.affiliation: Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Glenn
authors.affiliation: Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.
authors.forename: Gale E
authors.initials: GE
authors.lastname: Smith
authors.affiliation: Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.
authors.forename: David C
authors.initials: DC
authors.lastname: Flyer
authors.affiliation: University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States. Electronic address: mfrieman@som.umaryland.edu.
authors.forename: Matthew B
authors.initials: MB
authors.lastname: Frieman
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D018352:Coronavirus Infections / Q000517:prevention & control*; D004195:Disease Models, Animal; D008807:Mice, Inbred BALB C; D065207:Middle East Respiratory Syndrome Coronavirus / Q000235:genetics / Q000276:immunology*; D064370:Spike Glycoprotein, Coronavirus / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D058425:Vaccines, Virus-Like Particle / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D064370:Spike Glycoprotein, Coronavirus; D014614:Vaccines, Synthetic; D058425:Vaccines, Virus-Like Particle; D014765:Viral Vaccines
keywords: Coronavirus; MERS-CoV; Mouse model; Nanoparticle vaccine